Back to MPT Database

EVO100 Gel

The Phase 2b study evaluating EVO100 Gel for the prevention of chlamydia and gonorrhea met its primary and secondary endpoints, and was generally safe and well tolerated. It has been granted Fast Track Designation for the prevention of chlamydia in women and Qualified Infectious Disease Product (QIDP) Designation for the prevention of gonorrhea in women by the U.S. Food and Drug Administration (FDA). As of 2020, Phase 3 trials for the contraceptive indication are complete and has been approved in the United States by the FDA under the brand name Phexxi™.

Development Stage:

Clinical – Phase 3 Trial (C3)

Hormonal/Non-Hormonal:

Non-Hormonal

Delivery Route & Method:

Topical - Gel-Vaginal

Mechanism of Action:

Vaginal pH regulation

Developer:

  • Evofem Biosciences, Inc.

Funding:

  • Evofem Biosciences, Inc.

Back to MPT Database